GO
Loading...

Amgen Inc

More

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • This measure says stocks are really cheap…maybe Thursday, 22 Jan 2015 | 12:26 PM ET
    Traders on the floor of the New York Stock Exchange.

    One valuation measure has sparked a debate among strategists as to whether the stock market is really, really cheap.

  • Meet Morningstar's fund managers of the year Wednesday, 21 Jan 2015 | 5:42 PM ET
    Stock performance chart on computer screen

    Here are the fund managers Morningstar considers the best of the best.

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Jan 7- A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the regulator's first approval of a biosimilar. The biosimilar could be priced at the same level as Neupogen, but cost to insurers and consumers would be lower, Novartis executives...

  • Jan 7- A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, paving the way for the regulator's first approval for a biosimilar. The injectable biologic, Neupogen, prevents infections in breast cancer patients undergoing chemotherapy, which reduces their white...

  • Midday movers: Exxon Mobil, Chevron, Hess & more Monday, 5 Jan 2015 | 12:56 PM ET
    Wall Street New York Stock Exchange NYSE American Flags

    Some of Monday's midday movers:

  • Jan 5- Amgen Inc and Kite Pharma Inc said they entered into a deal to develop and market cancer immunotherapies using Amgen's cancer targets and Kite's technology platform. Amgen will pay Kite Pharma $60 million upfront and fund research costs through the filing of a new drug application. Kite will be eligible to receive up to $525 million per Amgen program...

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount. Express Scripts' move reignited investor concerns that pharmaceutical companies...

  • Dec 19- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission. AstraZeneca expects potential sales of around $2 billion a year from the drug. London- based AstraZeneca's U.S.-listed shares were down about 1 percent at $71.41 in afternoon...

  • Leaked Sony emails show Loeb influence on studio execs Wednesday, 17 Dec 2014 | 3:11 PM ET

    TOKYO/ BOSTON, Dec 17- Sony Corp movie executives kept up a dialogue with hedge fund titan Daniel Loeb, even after rebuffing the billionaire investor's proposal to sell up to one-fifth of the studio's entertainment business, leaked emails show. Loeb's New York- based Third Point took a 7 percent stake in the company in May 2013 and suggested that proceeds from a...

  • Midday Movers: Carnival, Chevron, Netflix & more Wednesday, 17 Dec 2014 | 12:59 PM ET
    Wall Street subway station NYSE

    Some of Wednesday's midday movers:

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...